Combination Drug Therapy with Olaparib in Epithelial Ovarian Cancer:an Overview
Olaparib,the first polyadenosine diphosphate-ribose polymerase(PARP)inhibitor developed for ovarian cancer,has been widely used as a maintenance therapy for epithelial ovarian cancer,significantly prolonging patient survival.However,some patients still experience poor single-agent efficacy or progressive drug resistance.The combination of olaparib with drugs such as vascular endothelial growth factor(VEGF)inhibitors,tyrosine kinase inhibitors(TKIs),immune checkpoint inhibitors(ICIs),chemotherapy agents,and ATR inhibitors can delay or overcome treatment resistance and enhance drug sensitivity through synergistic effects between drugs in patients with epithelial ovarian cancer.The combination drug therapy with olaparib for epithelial ovarian cancer can positively improve prognosis,particularly in the population of patients carrying BRCA gene mutations,where its efficacy is more significant.However,the safety and long-term effectiveness still need to be demonstrated through larger-scale clinical trials.
NETL
NSTL
万方数据
